| DC47561 |
MHY-1685
|
MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration.
|
| DC11816 |
RapaLink-1
|
RapaLink-1 is a third-generation mTOR inhibitor that overcomes resistance to existing first- and second-generation inhibitors; blocks mTOR signaling of the F2108L mTOR and M2327I mTOR drug resistant mutants; RapaLink-1 is more potent mTOR inhibitor than rapamycin. |
| DC1006 |
OSI-027
|
OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, respectively. |
| DC7210 |
LY-303511(Nv-128)
|
LY303511, an inactive analogue of LY294002, is a mTOR inhibitor that did not inhibit PI3-K. |
| DC7171 |
INK-128(Sapanisertib)
|
INK 128 is a potent and selective mTOR inhibitor with IC50 of 1 nM; >200-fold less potent to class I PI3K isoforms. |
| DC11866 |
AZD 3147
|
A potent, selective dual mTORC1 and mTORC2 inhibitor with enzyme IC50 of 1.5 nM. |
| DC74258 |
NV-5297
|
NV-5297 (NV5297) is a novel small molecule mTORC1 pathway activator, modulates the Sestrin2-Gator2 interaction and activates the mTORC1 pathway in vitro and in vivo. |
| DC72910 |
CC214-1
|
CC214-1 is a potentially efficacious mTOR inhibitor that induces autophagy ,with an IC50 is 0.002 μM. CC214-1 proved to be useful as an in vitro tool compound for the exploration of mTOR kinase biology. CC214-1 can be used for Glioblastoma study. |
| DC71229 |
PP30
|
PP30, a TORKinib, is a potent, selective, and ATP-competitive inhibitor of mTOR with an IC50 of 80 nM. |
| DC71016 |
CC214-2
|
CC214-2 is a potent and dual inhibitor of mTORC1/mTORC2. Mycobacterium tuberculosis modulates mammalian target of rapamycin (mTOR) signaling to impede autophagy. CC214-2 has the potential to shorten the duration of TB. |
